JPMorgan Chase Boosts Illumina Stake by 17.5%

Investment firm adds over 124,000 shares of life sciences company in Q3

Mar. 19, 2026 at 9:21am

Got story updates? Submit your updates here. ›

JPMorgan Chase & Co. increased its holdings in Illumina, Inc. (NASDAQ:ILMN) by 17.5% in the third quarter, according to a recent SEC filing. The firm now owns 832,690 shares of the life sciences company's stock, valued at $79,081,000.

Why it matters

Illumina is a leading provider of DNA sequencing systems and related products, playing a key role in the growing field of genomics research and clinical applications. JPMorgan's increased stake signals the investment firm's confidence in Illumina's long-term growth potential.

The details

According to the filing, JPMorgan Chase added 124,246 shares of Illumina during the third quarter, bringing its total position to over 832,000 shares. This represents a 17.5% increase in the firm's holdings of the life sciences company's stock.

  • The filing covers the third quarter of 2026.

The players

JPMorgan Chase & Co.

A multinational investment bank and financial services company headquartered in New York City.

Illumina, Inc.

A global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function.

Got photos? Submit your photos here. ›

The takeaway

JPMorgan Chase's increased stake in Illumina reflects the investment firm's confidence in the life sciences company's growth prospects, particularly in the rapidly evolving field of genomics research and clinical applications.